Compare VZLA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | TRVI |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2019 | 2019 |
| Metric | VZLA | TRVI |
|---|---|---|
| Price | $4.13 | $13.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $7.00 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 5.8M | 1.2M |
| Earning Date | 12-12-2025 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.82 | $5.38 |
| 52 Week High | $7.19 | $16.12 |
| Indicator | VZLA | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 66.26 | 48.07 |
| Support Level | $3.22 | $13.12 |
| Resistance Level | $4.33 | $14.39 |
| Average True Range (ATR) | 0.23 | 0.66 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 93.30 | 30.15 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.